Impaired T helper type 1 (Th1) function is implicated in the susceptibility of patients with chronic obstructive pulmonary disease (COPD) to respiratory infections, which are common causes of acute exacerbations of COPD (AECOPD). To understand the underlying mechanisms, we assessed regulatory T (Treg) cells and the expression of an inhibitory Tcell receptor, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Cryopreserved peripheral blood mononuclear cells (PBMC) from patients with AECOPD (n = 17), patients with stable COPD (sCOPD; n = 24) and age-matched healthy non-smoking controls (n = 26) were cultured for 24 hr with brefeldin-A or monensin to detect intracellular or surface CTLA-4 (respectively) by flow cytometry. T cells in PBMC from AECOPD (n = 9), sCOPD (n = 14) and controls (n = 12) were stimulated with anti-CD3 with and without anti-CTLA-4 blocking antibodies and cytokines were quantified by ELISA. Frequencies of circulating T cells expressing intracellular CTLA-4 were higher in sCOPD (P = 0Á01), whereas patients with AECOPD had more T cells expressing surface CTLA-4 than healthy controls (P = 0Á03). Increased frequencies of surface CTLA-4 + CD4 + T cells and CTLA-4 + Treg cells paralleled increases in plasma soluble tumour necrosis factor receptor-1 levels (r = 0Á32, P = 0Á01 and r = 0Á29, P = 0Á02, respectively) in all subjects. Interferon-c responses to anti-CD3 stimulation were inversely proportional to frequencies of CD4 + T cells expressing intracellular CTLA-4 (r = À0Á43, P = 0Á01). Moreover, CTLA-4 blockade increased the induction of interferon-c, tumour necrosis factor-a and interleukin-6 in PBMC stimulated with anti-CD3. Overall, chronic inflammation may expand sub-populations of T cells expressing CTLA-4 in COPD patients and therefore impair T-cell function. CTLA-4 blockade may restore Th1 function in patients with COPD and so aid the clearance of bacterial pathogens responsible for AECOPD.
Summary
Impaired T helper type 1 (Th1) function is implicated in the susceptibility of patients with chronic obstructive pulmonary disease (COPD) to respiratory infections, which are common causes of acute exacerbations of COPD (AECOPD). To understand the underlying mechanisms, we assessed regulatory T (Treg) cells and the expression of an inhibitory Tcell receptor, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Cryopreserved peripheral blood mononuclear cells (PBMC) from patients with AECOPD (n = 17), patients with stable COPD (sCOPD; n = 24) and age-matched healthy non-smoking controls (n = 26) were cultured for 24 hr with brefeldin-A or monensin to detect intracellular or surface CTLA-4 (respectively) by flow cytometry. T cells in PBMC from AECOPD (n = 9), sCOPD (n = 14) and controls (n = 12) were stimulated with anti-CD3 with and without anti-CTLA-4 blocking antibodies and cytokines were quantified by ELISA. Frequencies of circulating T cells expressing intracellular CTLA-4 were higher in sCOPD (P = 0Á01), whereas patients with AECOPD had more T cells expressing surface CTLA-4 than healthy controls (P = 0Á03). Increased frequencies of surface CTLA-4 + CD4 + T cells and CTLA-4 + Treg cells paralleled increases in plasma soluble tumour necrosis factor receptor-1 levels (r = 0Á32, P = 0Á01 and r = 0Á29, P = 0Á02, respectively) in all subjects. Interferon-c responses to anti-CD3 stimulation were inversely proportional to frequencies of CD4 + T cells expressing intracellular CTLA-4 (r = À0Á43, P = 0Á01). Moreover, CTLA-4 blockade increased the induction of interferon-c, tumour necrosis factor-a and interleukin-6 in PBMC stimulated with anti-CD3. Overall, chronic inflammation may expand sub-populations of T cells expressing CTLA-4 in COPD patients and therefore impair T-cell function. CTLA-4 blockade may restore Th1 function in patients with COPD and so aid the clearance of bacterial pathogens responsible for AECOPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the top five causes of morbidity and mortality worldwide.
Smoking is the most common cause of COPD, but genetic factors and environmental pollutions are also implicated. 1 The disease is characterized by progressive limitation of airflow, with abnormal inflammatory responses to inhaled particles or gases. 2 The chronic inflammation of the airways involves infiltration and activation of neutrophils, macrophages and T cells. [3] [4] [5] Subsequent systemic inflammation contributes to co-morbidities (e.g. cardiovascular disease and cachexia). 6 Most patients are relatively stable with treatment (sCOPD), but some experience acute exacerbations of COPD (AECOPD), which increase mortality and morbidity. 7 AECOPD is defined as 'an event in the natural course of the disease characterized by a change in the patient's baseline dyspnoea, cough and/or sputum, and beyond normal day-to-day variations, that is acute in onset and may warrant a change in regular medication in a patient with underlying COPD'. 2 Respiratory bacterial infections account for up to 50% of AECOPD events. Non-typeable Haemophilus influenzae (NTHI), Streptococcus pneumoniae and Moraxella catarrhalis are the major bacterial pathogens isolated from patients with AECOPD. 8 As NTHI oral vaccines do not reduce the frequency and severity of AECOPD, 9 the capacity to mount a protective anti-bacterial immune response may be limited in patients with COPD.
Despite its inflammatory aetiology, COPD is considered as an immune-deficient state as the abundant activated T cells in the airways of COPD patients do not eradicate bacterial infections. Indeed, T helper type 1 (Th1) immune responses [e.g. production of interferon-c (IFNc) and phagocytosis] are impaired in patients with COPD. [10] [11] [12] [13] Exogenous IFN-c can enhance killing of NTHI by monocytes from patients with bronchiectasis, 14 confirming the necessity for appropriate Th1 responses for clearance of bacterial infections. Here we address the regulators of T-cell responses in patients with COPD and search for means to improve host production of IFN-c.
An important regulator of T-cell function is cytotoxic T-lymphocyte antigen-4 (CTLA-4), which blocks the CD28-mediated activation of T cells. 15 CTLA-4 is constitutively expressed by regulatory T (Treg) cells and activated effector T cells. It inhibits the proliferation of T cells and the production of pro-inflammatory cytokines, and so prevents continuous T-cell activation. 15, 16 Polymorphisms in the gene encoding CTLA-4 (e.g. rs231775 and rs5742909) and increased serum levels of the soluble form of CTLA-4 have been associated with dysregulated T-cell responses and increased susceptibility to COPD and chronic bronchitis. [17] [18] [19] [20] 24 Here in a larger patient cohort, we address the possibility that chronic inflammation in patients with COPD may increase CTLA-4 expression or proportions of Treg cells which constitutively express CTLA-4, so limiting protective Th1-cell responses (e.g. IFN-c production). Little is known about the role of CTLA-4 in AECOPD in terms of levels of expression and anti-bacterial function. Furthermore, most studies have only assessed intracellular expression as surface expression is complicated by the rapid endocytosis of CTLA-4. Hence we have addressed the expression of intracellular and surface CTLA-4 using novel assays and hypothesized that the expression of CTLA-4 is elevated in AECOPD, which reduces antibacterial responses such as IFN-c production.
Methods

Study subjects and sample collection
Patients with AECOPD (n = 17; 7 current smokers and 10 ex-smokers) were recruited on admission to the Emergency Department in Royal Perth Hospital in Western Australia. Patients with stable COPD (sCOPD; n = 24, all ex-smokers) were recruited from a dedicated COPD clinic at Royal Perth Hospital. All AECOPD and sCOPD patients had a smoking history of > 15 pack-years and ex-smokers were defined as those who had ceased smoking > 1 year earlier. The diagnosis and severity of COPD was established by a respiratory physician according to the GOLD criteria (Stages 2-4). 25 All patients with COPD had been treated with anticholinergic drugs, long-acting beta agonists and inhaled corticosteroids for >3 months before participating in the study. Co-morbidities included hypertension, osteoporosis and ischaemic heart disease. No patients were receiving systemic corticosteroids or had diabetes, neuromuscular, allergic or rheumatological disease. Age-matched healthy non-smoking controls with no clinical evidence of COPD and not taking any antibiotics or anti-inflammatory medications were tested in parallel (HC; n = 26). This study was approved by the Royal Perth Hospital Human Research Ethics Committee (EC2012/23) and all participants gave informed consent.
Blood samples were collected in lithium heparin tubes, centrifuged at 1000 g for 10 min and plasma was stored in aliquots at À80°. PBMC were isolated by Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare, Uppsala, Sweden) and cryopreserved in 10% DMSO/fetal calf serum (FCS; Gibco by Invitrogen, Carlsbad, CA).
T-cell subsets
The PBMC (1 9 10 6 cells/ml) were cultured at 37°in 5% CO 2 for 24 hr in polypropylene tubes on a 5-degree incline in 10% FCS/RPMI. BD GolgiPlug TM (Brefeldin-A 1 lg/ml) or BD GolgiStop TM (monensin; 2 lM) plus CTLA-4-allophycocyanin (APC) antibodies (BD Biosciences, San Jose, CA) was added after 2 hr. Brefeldin-A prevents secretion of proteins including CTLA-4 and hence measures intracellular CTLA-4. As surface expression of CTLA-4 is transient due to rapid endocytosis, PBMC were cultured in the presence of CTLA-4-APC antibodies plus monensin (which prevents acidification and subsequent degradation of endocytosed CTLA-4 antibody complexes) before staining for immunophenotypic markers. Cells were washed and stained with the BD Horizon TM Fixable Viability Stain 450, followed by surface-staining with CD3-APC-H7, CD4-V500, CD8-Peridinin chlorophyll protein-Cy5.5 and CD45RA-phycoerythrin-Cy7 antibodies. Intracytoplasmic staining was done using the BD Pharmingen TM Human Foxp3 buffer sets with Foxp3-phycoerythrin and CTLA-4-APC antibodies (BD Biosciences). A total of 200 000 events were acquired using a BD FACSCanto II cytometer and analysed with FLOWJO (Fig. S1 ).
CTLA-4 blocking assay
The PBMC (2 9 10 5 cells/well at 1 9 10 6 cells/ml) from nine patients with AECOPD, 14 patients with sCOPD and 12 controls were stimulated with 10 ng/ml anti-CD3 (Mabtech, Nacka Strand, Sweden), with or without 10 lg/ml anti-CTLA-4 antibody (clone BNI3; BD Biosciences) for 24 hr in 96-well flat-bottom plates. Culture supernatants were stored at À80°C. To measure T-cell production of IFN-c or tumour necrosis factor-a (TNFa), PBMC (1 9 10 6 cells/ml) from six participants (AECOPD, n = 2; sCOPD, n = 2; controls, n = 2) were cultured with 10 ng/ml anti-CD3 for 24 hr, with or without 10 lg/ml anti-CTLA-4 antibody. Brefeldin-A was added 2 hr after the start of culture. Cells were washed and stained with the BD Horizon TM Fixable Viability Stain 450, followed by surface-staining with CD3-V500, CD4-PerCP and CD8-APC-H7 antibodies (BD Biosciences). Intracytoplasmic staining was performed using the BD Cytofix Cytoperm TM buffer sets, IFN-c-BV421 and TNF-aphycoerythrin antibodies (BD Biosciences). In all, 200 000 events were acquired using a BD FACSCanto II cytometer and analysed with FLOWJO v5Á7Á2 software (Tree Star).
Quantification of soluble biomarkers
Plasma levels of CRP and soluble TNF receptor-1 (sTNFR1) were measured by ELISA (R&D Systems, Minneapolis, MN). Concentrations of IFN-c, interleukin-6 (IL-6), IL-10 and TNF-a (BD Biosciences) were measured in culture supernatants by ELISA with the diluent (10% FCS/PBS) as a negative control. A sample with known cytokine concentrations (QC) was assayed on each plate to assess inter-plate variation (coefficient of variance was < 10%).
Data analysis
Non-parametric Mann-Whitney U-tests were used to compare data between groups. Wilcoxon matched-pairs signed rank tests were used to compare data within groups (e.g. with and without CTLA-4 blocking). Correlations were assessed using Spearman's rank correlation coefficients. All analyses were performed with GRAPHPAD PRISM 5Á04 software (GraphdPad Software, La Jolla, CA). Statistically significant differences (P < 0Á05) are indicated in the figures.
Results
Systemic inflammation in patients with AECOPD is higher than in sCOPD patients
Study demographics are presented in Table 1 . Relative to healthy controls, AECOPD and sCOPD patients exhibited increased systemic inflammation as defined by higher levels of plasma CRP (P < 0Á001 for both) and sTNFR1 (P = 0Á007 and P < 0Á001, respectively). Levels of CRP and sTNFR1 were also higher in patients with AECOPD than in sCOPD (P = 0Á02 and P = 0Á04, respectively; Table 1 ).
Patients with AECOPD exhibit higher frequencies of circulating Treg cells and CTLA-4 + T cells
The frequency of Treg cells (CD4 + CD25 + Foxp3 + ) was higher in patients with AECOPD than in sCOPD (P = 0Á01) or healthy controls (P = 0Á001), but similar in patients with sCOPD and controls (Fig. 1a) . Frequencies of total and memory (CD45RA neg ) CD4 + and CD8 + T cells were similar in all groups (data not shown). The frequency of Treg cells expressing intracellular CTLA-4 was higher in patients with sCOPD than in controls (P = 0Á01; Fig. 1b) and correlated with plasma levels of sTNFR1 (r = 0Á26, P = 0Á04). The frequency of CD4 + T cells expressing intracellular CTLA-4 was marginally higher in patients with sCOPD than controls (P = 0Á06; Fig. 1c) . Expression of intracellular CTLA-4 was low in CD8 + T cells (< 5%) and did not differ between groups (Fig. 1d) .
Interestingly, the frequency of surface CTLA-4 + Treg cells or CD4 + T cells are significantly lower than the frequency of intracellular CTLA-4 + Treg cells or CD4 + T cells, respectively (P < 0Á0001; Fig. 1b versus 1e and Fig. 1c versus 1f, respectively) . The median frequency of surface CTLA-4 + Treg cells was higher in patients with AECOPD than in patients with sCOPD (P = 0Á15) or controls (P = 0Á17), but the difference was not significant (Fig. 1e) . Patients with AECOPD had a higher frequency of CD4 + T cells with surface CTLA-4 + than controls (P = 0Á03), but there was no increase in patients with sCOPD (Fig. 1f) . Levels of sTNFR1 correlated with the proportion of surface CTLA-4 + Treg cells (r = 0Á29, P = 0Á02) and surface CTLA-4 + CD4 + T cells (r = 0Á32, P = 0Á01). Few CD8 + T cells expressed surface CTLA-4 (< 1%). The proportions of Treg cells, CD4 + T cells or CD8 + T cells expressing intracellular or surface CTLA-4 did not differ between patients with AECOPD who were current smokers compared with those who were ex-smokers (P = 0Á67 to P = 1Á00).
Levels of pro-inflammatory cytokines induced by anti-CD3 were increased by CTLA-4 blockade in all subjects
Sufficient PBMC were available from nine patients with AECOPD, 14 patients with sCOPD and 12 healthy controls. PBMC were cultured with anti-CD3 to induce a pan T-cell response, with or without added anti-CTLA-4 antibody. Levels of IFN-c, TNF-a, IL-6 and IL-10 in supernatants of PBMC cultured with anti-CD3 only (no CTLA-4 blockade) were similar in the three groups ( Fig. 2a-d) . Overall the production of IFN-c correlated inversely with the proportions of Treg cells (r = À0Á46, P = 0Á004) and intracellular CTLA-4 + CD4 + T cells (r = À0Á52, P < 0Á001).
CTLA-4 blockade increased the anti-CD3-induced IFN-c, TNF-a and IL-6 responses of PBMC from healthy controls, and patients with sCOPD and AECOPD (Fig. 2a-c) , whereas IL-10 levels were marginally reduced (P = 0Á10 to P = 0Á32; Fig. 2d ). In a pilot study of two patients with AECOPD, two with sCOPD and two healthy controls analysed as a group, CTLA-4 blockade increased the proportions of IFN-c + or TNF-a + CD4 + and CD8 + T cells (Fig. 2e) . Hence CTLA-4 blockade may promote production of pro-inflammatory cytokines while inhibiting the production of IL-10.
Discussion
Acute exacerbations in patients with COPD are commonly associated with respiratory infections, 8 reflecting impaired Th1 responses to bacteria. [10] [11] [12] [13] For example; in vitro lymphoproliferative responses to NTHI protein P6 were lower in patients with AECOPD whose sputum was culture positive for NTHI than in patients with COPD with no exacerbations attributed to NTHI. 12 However, the underlying mechanisms have not been elucidated. Here, we provide novel data to support a role for CTLA-4 and Treg cells in limiting protective Th1 responses in patients with AECOPD. Expression of surface (not intracellular) CTLA-4 in patients with AECOPD was increased and associated with impaired IFN-c responses. Furthermore, the blockade of CTLA-4 improved production of Th1 cytokines.
Compared with controls, the frequencies of circulating CD4 + T cells and Treg cells expressing intracellular CTLA-4 were higher in patients with sCOPD, whereas 26 Importantly, we have linked the increased proportions of CD4 + T cells and Treg cells expressing surface CTLA-4 with increased levels of plasma sTNFR1. We suggest that chronic inflammation experienced by all patients with COPD may expand populations of intracellular CTLA-4 + CD4 + T cells and CTLA-4 + Treg cells. Episodes of AECOPD may then further activate these cells, promoting the cycling of CTLA-4 between intracellular compartments and the cell surface, as shown previously in PHA-activated PBMC. 27 This is the first demonstration of the critical need to distinguish surface from intracellular CTLA-4 in patients with AECOPD and patients with sCOPD.
Splice variants of the CTLA-4 gene may result in the expression of the transmembrane isoform (Tm-CTLA-4) or soluble isoform which lacks the transmembrane domain (sCTLA-4). The expression of both isoforms can be induced by activated CD4 + T cells and both are immunosuppressive. Hence, increased cycling of CTLA-4 (e.g. during an AECOPD episode) could reflect increases in both transmembrane and soluble CTLA-4 because the commercially available clone of anti-CTLA-4 antibody (BNI3) used in our study targets both CTLA-4 isoforms. Future study should investigate the role of sCTLA-4 versus Tm-CTLA-4 in AECOPD using an anti-CTLA-4 antibody clone that specifically targets the sCTLA-4 isoform (e.g. those generated by Esposito et al. 28 ). The production of IFN-c was associated inversely with the proportions of circulating Treg cells and intracellular CTLA-4 + CD4 + T cells. Furthermore, the production of IFN-c, TNF-a and IL-6 by PBMC and proportions of 29, 30 Our data support the use of CTLA-4 blockade to restore Th1 responses (e.g. IFN-c production) in patients with COPD, which in turn should aid clearance of bacterial and/or viral pathogens, so reducing the risk of AECOPD. The blockade of 'immune checkpoints' such as CTLA-4 has been used to inhibit Treg cell function and promote effector T-cell responses, 31 showing promising clinical results in anti-tumour treatment. 32 Similarly in mice infected with Nippostrongylus brasiliensis, Listeria monocytogenes or Mycobacterium bovis, CTLA-4 blockade enhanced the production of IFN-c and TNF-a.
33-35
Although we had no access to cells from the lung, the observed increase in proportions of Treg cells matches that seen in bronchoalveolar lavage and lymphoid follicles from patients with COPD. 23, 36 As responses by PBMC may not reflect respiratory mucosal responses to NTHI, studies of CTLA-4 expression by T-cells from the lung and challenge with bacteria implicated in AECOPD episodes (e.g. NTHI) are warranted to establish CTLA-4 blockade as a viable therapeutic strategy to improve the production of Th1 cytokines.
